

decreases in the occurrence of resistance to 46.7% and 28.1% among *E faecium* and *E faecalis* isolates from pigs, respectively. Erythromycin resistance among *E faecium* isolates from broilers reached a maximum of 76.3% in 1997, but decreased to 12.7% in 2000 concomitantly with more limited use of virginiamycin. Use of virginiamycin increased from 1995 to 1997 and was followed by an increased occurrence of virginiamycin resistance among *E faecium* isolates in broilers—from 27.3% in 1995 to 66.2% in 1997. In January 1998, the use of virginiamycin was banned in Denmark, and the occurrence of virginiamycin resistance decreased to 33.9% in 2000.

Use of avilamycin increased from 1995 to 1996 and was followed by an increase in avilamycin resistance among *E faecium* isolates from broilers, from 63.6% in 1995 to 77.4% in 1996. Since 1996, avilamycin usage has decreased, followed by a decrease in resistance to 4.8% in 2000. These results show that it is possible to reduce the occurrence of antimicrobial resistance in a national population of food animals when the selective pressure is removed. Cases in which resistance to vancomycin was linked to resistance to erythromycin were exceptions. In such cases, resistance did not decrease until the use of both avoparcin and tylosin was limited.

FROM: Aarestrup FM, Seyfarth AM, Emborg HD, Pedersen K, Hendriksen RS, Bager F. Effect of abolishment of the use of antimicrobial agents for growth promotion on occurrence of antimicrobial resistance in fecal enterococci from food animals in Denmark. *Antimicrob Agents Chemother* 2001;45:2054-2059.

AHRQ Issues Report on Evidence-Based Practice for Patient Safety

The Agency for Healthcare Research and Quality (AHRQ) recently released a report, *Making Health Care Safer, A Critical Analysis of Patient Safety Practices*. The report reviews data on 79 specific patient safety practices. Among the 11 “highly proven” practices (mostly clinical interventions) are pre-operative administration of antibiotics to prevent infections and beta-blockers to prevent heart attacks during or after surgery. Researchers from the University of California at San Francisco, Stanford University, were commissioned by AHRQ to prepare the report for AHRQ. The report is based on a review of the medical literature on safety practices and on consultation with healthcare experts, focusing on issues relevant to care delivered in hospitals and on prevalent diseases and procedures. Practices were excluded if there were few or no scientific studies to support them, and more than a dozen practices long considered important by patient safety experts did not make the list.

The five chapters in the “Infection Control” section address handwashing compliance; barrier precautions; impact of antibiotic-use practices; and prevention of nosocomial urinary tract infections, intravascular catheter-associated infections, and ventilator-associated pneumonia. The chapters are all structured similarly, providing back-

ground on the practice in question, opportunities for impact, study design and outcomes, evidence for effectiveness, potential for harm, cost of implementation, and a concluding comment. The narrative is followed by a tabular listing of studies, including description of the interventions, type of study design, and statistical results. Each chapter concludes with actual study citations.

AHRQ recognizes that there are gaps in each area, that more research is needed to determine which practices are most effective in improving patient safety, and that it needs to be determined how complex or costly they would be to implement. The National Forum for Health Care Quality Measurement and Reporting, a coalition of providers, consumers, purchasers, employers, and accrediting bodies, intends to use the report to develop a checklist of measures that patients may use to determine the actions hospitals and health facilities have taken to improve safety.

The report can be obtained by calling the AHRQ Publications Clearinghouse at (800) 358-9295 or sending an e-mail message to ahrqpubs@ahrq.gov. The report can be downloaded from the AHRQ web site as a pdf file, or viewed or printed online by chapter at www.ahrq.gov/clinic/ptsafety.

Enterococcus faecalis Surface Protein and Urinary Tract Infections

Enterococcus faecalis isolated from patients with bacteremia, endocarditis, and urinary tract infections more frequently express the surface protein Esp than do fecal isolates. Shankar and colleagues from the University of Oklahoma Health Sciences Center, Oklahoma City, conducted a study to assess the role of Esp in colonization and persistence of *E faecalis* in an animal model of ascending urinary tract infection. They compared an Esp(+) strain of *E faecalis* to its isogenic Esp-deficient mutant. Groups of CBA/J mice were challenged transurethrally with 10^8 colony-forming units of either the parent or mutant strain; bacteria in the urine, bladder, and kidneys were enumerated 5 days postinfection.

Significantly higher numbers of bacteria were recovered from the bladder and urine of mice challenged with the parent strain than from the bladder and urine of mice challenged with the mutant. Colonization of the kidney, however, was not significantly different between the parent and mutant strains. Histopathological evaluations of kidney and bladder tissue done at 5 days' postinfection did not show marked histopathological changes consistent with inflammation, mucosal hyperplasia, or apoptosis, and there was no observable difference between the mice challenged with the parent and those challenged with the mutant.

The authors concluded that, while Esp does not influence histopathological changes associated with acute urinary tract infections, it contributes to colonization and persistence of *E faecalis* at this site.

FROM: Shankar N, Lockett CV, Baghdayan AS, Drachenberg C, Gilmore MS, Johnson DE. Role of